Road to 2025: Race on track with clinical trials
Road to 2025: Race on track with clinical trials
Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead. In this episode, Fraser Palamara takes a look at Race Oncology (ASX:RAC). Watch the video...
Behind Race Oncology’s quest to prevent chemo from being worse than the disease
Behind Race Oncology’s quest to prevent chemo from being worse than the disease
Race Oncology is reformulating bisantrene (RAC-220) to prevent chemotherapy-induced heart damage, with a phase 1 cardioprotection trial planned for early 2025. The trial will enroll 25-40 patients across multiple sites. The company has also...
The Australian: Race Oncology bolsters leadership with key appointment
The Australian: Race Oncology bolsters leadership with key appointment
As seen in The Australian, Dr Megan Baldwin joins the Race board as Non-Executive Director. Dr Baldwin is a seasoned biotech executive with more than 25 years of experience. She is the Founder and...
Proactive: Race Oncology secures A$5.25 million R&D tax rebate for FY2024
Proactive: Race Oncology secures A$5.25 million R&D tax rebate for FY2024
Proactive reports on Race’s R&D tax rebate and clinical progress made in FY 2024. Read the full article here....
The Australian: Race submits key ethics application for phase I cancer trial
The Australian: Race submits key ethics application for phase I cancer trial
Conducted in two stages, the Phase 1 clinical trial will examine the safety and tolerability of the reformulated bisantrene, RC220, in particular the drug’s cardioprotective ability when used in combination with doxorubicin, a form...
Proactive: Race Oncology submits human ethics for RC220 Phase 1 solid tumour trial
Proactive: Race Oncology submits human ethics for RC220 Phase 1 solid tumour trial
Race Oncology Ltd (ASX:RAC, OTC:RAONF) has taken another key step toward a Phase 1 trial in solid tumour patients using RC220 bisantrene by submitting an application for an ethics and regulatory package to Bellberry Human...
Proactive: Race Oncology advances RNA epigenetics with FTO drug discovery at Monash
Proactive: Race Oncology advances RNA epigenetics with FTO drug discovery at Monash
Race CEO Dr Daniel Tillett joins Proactive’s Tylah Tully to discuss the FTO drug discovery program the company has concluded at Monash University’s Fragment Platform (MFP). Watch the full interview below and for the...
ausbiz: Racing ahead – successful trial & board revamp at Race Oncology
ausbiz: Racing ahead – successful trial & board revamp at Race Oncology
CEO and MD Dr Daniel Tillett joined ausbiz post the release of September Quarterly Activity Report, reaffirming the company’s strong funding position, clinical pipeline, and noting changes in the Board and Management team. Watch...
Stockhead: HealthInvest 2024: The biotech sector looks in rude health, judging by these five ASX innovators
Stockhead: HealthInvest 2024: The biotech sector looks in rude health, judging by these five ASX innovators
Race Oncology joins four other biotech companies to present at HealthInvest 2024, hosted by IR Department, Morgans and Stockhead. At the conference, Race presented the clinical development history of its lead asset bisantrene, and...
Proactive: Race Oncology completes board renewal to drive next phase of growth
Proactive: Race Oncology completes board renewal to drive next phase of growth
Race Executive Chair Dr Peter Smith speaks with Proactive about the recent board changes and the company’s clinical pipeline for its lead drug asset, bisantrene. Read the full report here....
